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BI‐RADS

:   Breast Imaging Reporting and Data System

BMI

:   body mass index

BPE

:   background parenchymal enhancement

CI

:   confidence interval

DCIS

:   ductal carcinoma *in situ*

E1

:   estrone

E2

:   estradiol

FGT

:   fibroglandular tissue

MHT

:   menopausal hormone therapy

MPD

:   mammographic percent density

MRI

:   magnetic resonance imaging

MSK

:   Memorial Sloan Kettering Cancer Centre

SERM

:   selective estrogen receptor modulator

SHBG

:   sex hormone binding globulin

Introduction {#ijc31370-sec-0001}
============

Mammographic percent density (MPD) is a measure of the proportion of the normal breast occupied by fibroglandular tissue (FGT), seen as dense (white) areas on a mammogram. Studies have consistently demonstrated a strong relationship between MPD and risk of breast cancer.[1](#ijc31370-bib-0001){ref-type="ref"} In a large meta‐analysis, an overall relative risk (RR) for incident breast cancer of 4.6 (95% confidence interval (CI) 3.6--5.9) was observed for women with ≥75% *vs*. \<5% MPD.[1](#ijc31370-bib-0001){ref-type="ref"} Current recommendations in the United States are for women with a lifetime risk of breast cancer of ≥20% to undergo screening with contrast‐enhanced breast magnetic resonance imaging (MRI) as well as mammography.[2](#ijc31370-bib-0002){ref-type="ref"} As is the case for mammography, FGT and fat are the two primary components observed on breast MRI, which provides a volumetric assessment of FGT in the breast (MRI‐density). This measure has been shown to be highly correlated with MPD,[3](#ijc31370-bib-0003){ref-type="ref"}, [4](#ijc31370-bib-0004){ref-type="ref"}, [5](#ijc31370-bib-0005){ref-type="ref"} and like MPD, has been associated with breast cancer risk.[6](#ijc31370-bib-0006){ref-type="ref"}

Contrast‐enhanced MRI uses a contrast agent, which is injected intravenously, to aid in the visualization of tumors which often generate a distinct pattern of contrast dispersal.[7](#ijc31370-bib-0007){ref-type="ref"}, [8](#ijc31370-bib-0008){ref-type="ref"} This pattern, termed enhancement, helps to identify suspicious regions of interest for biopsy or follow‐up. Normal FGT also enhances to varying degrees on contrast‐enhanced MRI and is called background parenchymal enhancement (BPE). Having a high amount of BPE has been associated with breast cancer risk,[6](#ijc31370-bib-0006){ref-type="ref"}, [9](#ijc31370-bib-0009){ref-type="ref"} independent of the amount of MRI‐density.[6](#ijc31370-bib-0006){ref-type="ref"}

Estrogen is central to the etiology of breast cancer and circulating estrogen levels are associated with postmenopausal breast cancer risk.[10](#ijc31370-bib-0010){ref-type="ref"} MPD is known to be influenced by hormonal exposures including reduced MPD at menopause[11](#ijc31370-bib-0011){ref-type="ref"} and with tamoxifen treatment.[12](#ijc31370-bib-0012){ref-type="ref"}, [13](#ijc31370-bib-0013){ref-type="ref"} An increase in MPD is seen with use of menopausal hormone therapy (MHT), and this is more pronounced with the use of combined estrogen and progestin therapy.[14](#ijc31370-bib-0014){ref-type="ref"}, [15](#ijc31370-bib-0015){ref-type="ref"}, [16](#ijc31370-bib-0016){ref-type="ref"}, [17](#ijc31370-bib-0017){ref-type="ref"} Studies examining the association between MPD and serum hormone concentrations have largely been null.[18](#ijc31370-bib-0018){ref-type="ref"}, [19](#ijc31370-bib-0019){ref-type="ref"}, [20](#ijc31370-bib-0020){ref-type="ref"}, [21](#ijc31370-bib-0021){ref-type="ref"}, [22](#ijc31370-bib-0022){ref-type="ref"}, [23](#ijc31370-bib-0023){ref-type="ref"}, [24](#ijc31370-bib-0024){ref-type="ref"}

Like MPD, both MRI‐density[25](#ijc31370-bib-0025){ref-type="ref"}, [26](#ijc31370-bib-0026){ref-type="ref"}, [27](#ijc31370-bib-0027){ref-type="ref"} and BPE^25--31^ have been shown to be sensitive to hormonal exposures, but the relationship between MRI‐density, BPE and serum hormone levels has not been examined. The objective of our study was to examine the relationship between BPE and MRI‐density and serum hormone concentrations in a population of postmenopausal women, without cancer, undergoing breast MRI screening at Memorial Sloan Kettering Cancer Center (MSK).

Materials and Methods {#ijc31370-sec-0002}
=====================

Our study was reviewed and approved by the MSK Institutional Review Board, and written informed consent was obtained at the time of recruitment from all study participants.

Study population {#ijc31370-sec-0003}
----------------

Between August 2012 and March 2014, 505 women who had no prior history of any cancer (including DCIS, but excluding non‐melanoma skin cancer) as noted in their medical record were approached in the MRI clinic at MSK as part of a larger study of BPE and breast cancer risk factors. The majority of women screened at the clinic meet the criteria to be classified as high risk (i.e., ≥20% lifetime risk of breast cancer). Of the 451 women who volunteered to participate in the study, 16 women ultimately did not participate or were determined to be ineligible (insufficient proficiency in English: *n* = 2, or prior personal history of cancer not previously identified during medical record review: *n* = 14). An additional 14 women were excluded because their study questionnaire was incomplete (*n* = 2) or they were diagnosed with breast cancer within the 6 months following their breast MRI (*n* = 12). This left a study population of 421 women, 220 of whom were postmenopausal. Of these postmenopausal women, 159 (72%) consented to a blood draw for hormone analyses. For the purpose of the analysis reported here, 23 of these 159 women were excluded because they reported current use of MHT (*n* = 4) or of a selective estrogen receptor modulator (SERM) (tamoxifen *n* = 2, raloxifene *n* = 16) or aromatase inhibitor (*n* = 1). This left 136 postmenopausal women with hormone measures available for the current analysis (Fig. [1](#ijc31370-fig-0001){ref-type="fig"}).

![Summary of patient recruitment.](IJC-143-823-g001){#ijc31370-fig-0001}

Data collection {#ijc31370-sec-0004}
---------------

At the time of MRI, all women completed a self‐administered questionnaire collecting information on established breast cancer risk factors, including: age at menarche, age at menopause, parity (number of full‐term pregnancies, age at first full‐term pregnancy, time since last pregnancy), use of hormonal medications at the time of MRI (i.e., MHT, tamoxifen, raloxifene, aromatase inhibitors), current weight and height, family history of breast cancer and history of oophorectomy. Medical records were reviewed to confirm questionnaire data as available. Women were considered to be postmenopausal at the time of MRI if they had not had a menstrual period in the preceding six months.

Biospecimen collection {#ijc31370-sec-0005}
----------------------

Non‐fasting peripheral blood samples were collected for serum in red top Vacutainer™ collection tubes. Samples were collected at the time of MRI, just prior to contrast administration, and allowed to clot for 30 min at room temperature. Samples were then processed within 2 hr of collection, and aliquoted into barcoded cryotubes. All samples were stored at −20°C until the time of hormone analyses.

Contrast‐enhanced MRI and assessment of BPE and MRI‐density {#ijc31370-sec-0006}
-----------------------------------------------------------

Breast MRI examinations were performed using a dedicated surface breast coil with the patient in the prone position. Standard imaging protocols were followed and included a localizing sequence, followed by a T2‐weighted fat suppressed sequence, a T1‐weighted non‐fat saturated sequence, and a bilateral T1‐weighted simultaneous sagittal fat‐suppressed sequence performed before and three times after a rapid bolus injection of 0.1 mmol/l per kg of body weight of the contrast agent, gadopentetate dimeglumine (Magnevist, Bayer Healthcare Pharmaceuticals, Montville, NJ) delivered through an in‐dwelling IV catheter. The first post‐contrast MRI series were run following a 1 min delay and were run consecutively with each series taking approximately 2 min.

BPE was assessed using the T1‐weighted fat‐saturated sequence from the pre‐contrast and first post‐contrast series (the first post‐contrast series starts 1 min following the pre‐contrast series) and the subtraction image (subtraction of the pre‐contrast from the first post‐contrast images) in accordance with the recommendations of the proposed American College of Radiology Breast Imaging Reporting and Data System (BI‐RADS).[32](#ijc31370-bib-0032){ref-type="ref"}, [33](#ijc31370-bib-0033){ref-type="ref"} A single reader (JS) categorized BPE using the BI‐RADS four‐point scale as: minimal (\<25% of FGT demonstrating enhancement); mild (25--50%); moderate (\>50% to 75%) or marked (\>75%).[33](#ijc31370-bib-0033){ref-type="ref"} MRI‐density was classified using the BI‐RADS criteria of: predominantly fatty (\<25% of the breast comprised of FGT); scattered (25--50%); heterogeneously dense (\>50% to 75%) or extremely dense (\>75%).[34](#ijc31370-bib-0034){ref-type="ref"}

Although BPE and MRI‐density are usually both very similar in both breasts,[33](#ijc31370-bib-0033){ref-type="ref"} readings were conducted for both breasts and any potential discordance noted. In the single patient were there was discordance, the higher value was taken. Once all reads were complete, a random set of MRIs (*n* = 19) were re‐read for both BPE and MRI‐density to assess agreement between repeat reads. All these readings were made without knowledge of the serum hormone results.

Serum hormone analysis {#ijc31370-sec-0007}
----------------------

Serum estrone (E1) and estradiol (E2) concentrations were quantified by validated radioimmunoassays (RIAs) after organic solvent extraction and Celite column partition chromatography.[35](#ijc31370-bib-0035){ref-type="ref"}, [36](#ijc31370-bib-0036){ref-type="ref"}, [37](#ijc31370-bib-0037){ref-type="ref"} Chromatographic separation of the steroids was achieved by using different concentrations of toluene in isooctane and ethyl acetate in isooctane. A highly specific antibody was used in each RIA in conjunction with an iodinated tracer. Sex hormone binding globulin (SHBG) was quantified by use of a solid‐phase, two‐site, chemiluminescent immunometric assay using the Immulite analyzer (Siemens Healthcare Diagnostics, Deerfield, IL). SHBG concentration was utilized in a validated algorithm with E2 to calculate bioavailable (i.e., non‐SHBG‐bound) E2. (Note: with this validated algorithm, free E2 is a simple proportion of bioavailable E2.)[38](#ijc31370-bib-0038){ref-type="ref"}, [39](#ijc31370-bib-0039){ref-type="ref"}, [40](#ijc31370-bib-0040){ref-type="ref"} Quality control samples containing low, medium and high levels of the hormones and SHBG were included in each assay. The inter‐assay coefficients of variation ranged between 8% and 13%. The assay sensitivities for E1, E2 and SHBG were 15 pmol/l, 7.5 pmol/l and 1 nmol/l, respectively.

Statistical analysis {#ijc31370-sec-0008}
--------------------

Women were excluded if they had E2 concentrations \>128 pmol/l (35 pg/ml), indicating that they may not have been truly postmenopausal at the time of MRI/blood draw (*n* = 18).[23](#ijc31370-bib-0023){ref-type="ref"} The final sample size for all analyses was 118 postmenopausal women (Fig. [1](#ijc31370-fig-0001){ref-type="fig"}).

Prior to analysis, serum SHBG, E1, E2 and bioavailable E2 concentrations were transformed using a Box‐Cox transformation to achieve approximately normal distributions.[41](#ijc31370-bib-0041){ref-type="ref"} This procedure finds the power transformation (*λ*) of the values that best approximates a normal distribution (note: *λ* = 0 is the log transformation). With *λ* values of 0.25, −0.25, −0.75 and −0.25 for SHBG, E1, E2 and bioavailable E2 respectively, the data for all serum measures were normally distributed based on the Shapiro--Wilk test for normality[42](#ijc31370-bib-0042){ref-type="ref"} and visual inspection of histograms and QQ plots.

The mean concentrations and 95% confidence intervals (CI), of SHBG, E1, E2 and bioavailable E2 were calculated for each category of BPE and MRI‐density using the "means" statement in the glm procedure in the statistical analysis package program SAS 9.4 (SAS Institute, Inc., Cary, NC).

MRI‐density is a measure of the proportion of the breast occupied by FGT. Thus, for a fixed amount of FGT, MRI‐density decreases with increasing BMI,[43](#ijc31370-bib-0043){ref-type="ref"} and for this reason, all analyses involving MRI‐density included an adjustment for BMI. In BPE analyses all values were compared to the "minimal" BPE category using ANOVA and adjusting for multiple comparisons using the Dunnett\'s *t*‐test. Similarly, in MRI‐density analyses all values were compared to the "predominantly fatty" category. Statistical significance for a linear trend across categories of BPE and MRI‐density were calculated using the "contrast" statement in the glm procedure. Variables that were considered as potential confounders included age at MRI, BMI (BPE analysis only), race/ethnicity, age at menarche, parity, *BRCA* mutation status, oophorectomy, first degree family history of breast cancer and alcohol consumption.

Cohen\'s kappa coefficients were used to determine the concordance between repeat BPE and MRI‐density reads by the study radiologist. All statistical analyses were conducted using SAS 9.4.

Results {#ijc31370-sec-0009}
=======

Characteristics of the study population are shown in Table [1](#ijc31370-tbl-0001){ref-type="table"}. The median age at MRI was 57 years and 91% of study participants were White/Caucasian. The majority of women (92%) were undergoing breast MRI for high‐risk breast cancer screening. Other reasons for MRI included an abnormal screening mammogram and/or the presence of a lump in the breast (Table [1](#ijc31370-tbl-0001){ref-type="table"}). None of these women were diagnosed with breast cancer at the time of MRI or in the following 6 months. Most women (72%) had a first degree family history of breast cancer (mother or daughter), and about a fifth were known *BRCA1* or *BRCA2* mutation carriers. The majority of women (55%) had "minimal" BPE and 54% had "heterogeneously dense" breasts. There was no significant association between BPE and MRI‐density (Spearman rank correlation coefficient *r* = −0.08, *p* = 0.40) (Table [2](#ijc31370-tbl-0002){ref-type="table"}). Weighted Cohen\'s kappa coefficients for BPE and MRI‐density repeat reads were 0.93 (95% CI 0.80, 1.00) and 0.94 (95% CI 0.83, 1.00) respectively, i.e., "almost perfect agreement."

###### 

Characteristics of the study population *N* = 118

  Patient characteristics                                                    
  -------------------------------------------------------------------------- -------------------
  *Age at MRI (years)*                                                       
  Median (IQR)                                                               57.0 (54.4, 61.8)
  *Reason for MRI, N (%)* [a](#ijc31370-note-0002){ref-type="fn"}            
  Abnormal screening mammogram                                               19 (16.1)
  Lump in breast                                                             5 (4.2)
  High‐risk breast cancer screening                                          109 (92.4)
  Other                                                                      8 (6.8)
  *Race/ethnicity, N (%)*                                                    
  White/Caucasian                                                            107 (90.7)
  Black/African American                                                     7 (5.9)
  Asian                                                                      2 (1.7)
  Other                                                                      2 (1.7)
  *Body mass index (BMI, kg/m* [b](#ijc31370-note-0003){ref-type="fn"} *)*   
  Median (IQR)                                                               24.3 (22.0, 28.1)
  \<25                                                                       70 (59.3)
  25 to \<30                                                                 23 (19.5)
  ≥30                                                                        25 (21.2)
  *Age at menarche (years)*                                                  
  Median (IQR)                                                               12.3 (12.0, 13.0)
  *Parity, N (%)*                                                            
  Nulliparous                                                                32 (27.1)
  Parous                                                                     86 (72.9)
  *First degree family history of breast cancer, N (%)*                      
  No                                                                         33 (28.0)
  Yes                                                                        84 (71.2)
  Unknown                                                                    1 (0.8)
  *BRCA mutation status, N (%)* [b](#ijc31370-note-0003){ref-type="fn"}      
  Negative                                                                   22 (18.6)
  Positive                                                                   25 (21.2)
  Unknown                                                                    71 (60.2)
  *Bilateral oophorectomy, N (%)*                                            
  No                                                                         78 (66.1)
  Yes                                                                        40 (33.9)
  *Number of drinks per week, N (%)*                                         
  None                                                                       28 (23.7)
  \<7                                                                        73 (61.9)
  ≥7                                                                         17 (14.4)
  *Smoking status at MRI, N (%)*                                             
  No                                                                         116 (98.3)
  Yes                                                                        2 (1.7)

Abbreviations IQR: inter‐quartile range.

Women were asked to indicate all that apply. "Other" category includes women with a personal history of atypical hyperplasia or LCIS.

*BRCA* positive women includes those who were *BRCA1* positive (*n* = 14), *BRCA2* positive (*n* = 10) and a single carrier with a *BRCA1* variant of unknown significance.

###### 

Distribution of MRI measurements (*N* = 118)

                                         Background parenchymal enhancement (BPE)                                   
  ----------------- -------------------- ------------------------------------------ ----------- --------- --------- -----------
  **MRI‐density**   **Fatty**            12                                         5           1         0         18 (15.3)
                    **Scattered**        11                                         15          3         1         30 (25.4)
                    **Heterogeneous**    37                                         22          3         2         64 (54.2)
                    **Dense**            5                                          0           0         1         6 (5.1)
                    **Total, *N* (%)**   65 (55.1)                                  42 (35.6)   7 (5.9)   4 (3.4)   118

Spearman rank correlation coefficient: *r* = −0.08, *p* = 0.40.

Forty women reported having had a bilateral oophorectomy (Table [1](#ijc31370-tbl-0001){ref-type="table"}). Median age, BMI and serum E2 and E1 concentrations did not differ by oophorectomy status (results not shown). An additional 11 women reported having had a simple hysterectomy. These women ranged in age from 44 to 64 years. Though for some of these women their menopausal status could be considered ambiguous, all had E2 levels lower than the cut‐off for inclusion (i.e., 128 pmol/l), and all had higher concentrations of E1 than E2. This indicates that these women were postmenopausal at the time of MRI/blood draw, and all were retained in the analysis. Furthermore, when analyses were repeated using a more stringent E2 cut‐point (i.e., 92 pmol/l or 25 pg/ml), only one additional woman was excluded and the study results were unchanged.

Though exclusions for MHT use at the time of MRI were made (*n* = 4, see Fig. [1](#ijc31370-fig-0001){ref-type="fig"}), it is possible that women could have recently used MHT. Of the women included in the current analysis, 16 reported ever use of MHT or evidence of MHT use was found in the electronic medical record (EMR). Of these women, two had ambiguous data on when MHT use stopped. Another two women reported that they stopped using MHT in the same year of the MRI. For the remaining women the average number of years between stopping MHT and MRI was 8.6 years (range: 1--13). Given this information no further exclusion for MHT use were made.

Figure [2](#ijc31370-fig-0002){ref-type="fig"} shows the unadjusted mean concentrations and 95% CIs of serum hormones by category of BPE. There was no association between BPE and serum SHBG. Significant positive associations were seen between BPE and serum E1, E2 and bioavailable E2. Compared to women with "minimal" BPE, women who had "marked" BPE had significantly higher serum concentrations of E1 (90% increase, *p* ~trend~ across all categories = 0.001), E2 (150% increase, *p* ~trend~ = 0.001) and bioavailable E2 (158% increase, *p* ~trend~ = 0.001). As expected, BMI was positively associated with E1, E2 and bioavailable E2 concentrations. There was no significant association between BPE and BMI in this data. Still, including BMI in the model strengthened the association between serum estrogens and BPE somewhat leading to a 138% increase in E1 from minimal to marked enhancement (*p* ~trend~ = 0.001), a 239% increase for E2 (*p* ~trend~ = 0.001) and a 193% increase for bioavailable E2 (*p* ~trend~ = 0.001). The relationship between BPE and serum hormones did not vary appreciably following adjustment for age at MRI, family history of breast cancer or *BRCA* mutation status. Furthermore, results did not differ in analyses restricted to Caucasians, the only group with appreciable numbers (results not shown).

![Association between serum hormone concentrations and degree of BPE in postmenopausal women.](IJC-143-823-g002){#ijc31370-fig-0002}

Figure [3](#ijc31370-fig-0003){ref-type="fig"} shows the corresponding results for MRI‐density (including an adjustment for BMI). There was a positive association between MRI‐density and serum SHBG: compared to women with "predominantly fatty" breasts, those with "dense" breasts had 67% higher serum concentrations of SHBG (*p* ~trend~ = 0.011). As MRI‐density increased, serum concentrations of E1 E2 and bioavailable E2 tended to decrease (Fig. [3](#ijc31370-fig-0003){ref-type="fig"}). However, no statistically significant relationships were observed (*p* ~trend~ = 0.96, *p* ~trend~ = 0.42 and *p* ~trend~ = 0.07, respectively). After further adjustment for SHBG, the relationship between MRI‐density and bioavailable E2 was further attenuated (*p* ~trend~ = 0.31).

![Association between serum hormone concentrations and degree of MRI‐density in postmenopausal women, adjusted for BMI.](IJC-143-823-g003){#ijc31370-fig-0003}

Discussion {#ijc31370-sec-0010}
==========

BPE and MRI‐density are characteristics of normal breast tissue that are routinely assessed by radiologists from standard contrast‐enhanced MRI. Both measures have been shown to be influenced by hormonal exposures. This is the first study to examine the relationship between BPE and MRI‐density and serum hormone concentrations. We found a significant positive association between BPE and serum concentrations of E1, E2 and bioavailable E2. This significant positive association persisted following adjustment for multiple factors including BMI.

We[6](#ijc31370-bib-0006){ref-type="ref"} and others[9](#ijc31370-bib-0009){ref-type="ref"} have found BPE to be positively associated with breast cancer risk. BPE has also been shown to decrease with menopause,[25](#ijc31370-bib-0025){ref-type="ref"}, [28](#ijc31370-bib-0028){ref-type="ref"} oophorectomy[29](#ijc31370-bib-0029){ref-type="ref"} and in response to tamoxifen[26](#ijc31370-bib-0026){ref-type="ref"}, [30](#ijc31370-bib-0030){ref-type="ref"} or aromatase inhibitor[27](#ijc31370-bib-0027){ref-type="ref"}, [31](#ijc31370-bib-0031){ref-type="ref"} treatment. It is hypothesized that BPE may reflect the proliferative activity of the breast, influenced by both endogenous and exogenous hormonal exposures, and that it is not just how much breast tissue you have (i.e., MPD or MRI‐density) but how biologically active that tissue is that determines breast cancer risk.

We found no relationship between MRI‐density and serum concentrations of E1, E2 or bioavailable E2. Results from studies of the association between serum estrogens and MPD have been mixed, but have largely shown no association.[18](#ijc31370-bib-0018){ref-type="ref"}, [19](#ijc31370-bib-0019){ref-type="ref"}, [20](#ijc31370-bib-0020){ref-type="ref"}, [21](#ijc31370-bib-0021){ref-type="ref"}, [22](#ijc31370-bib-0022){ref-type="ref"}, [23](#ijc31370-bib-0023){ref-type="ref"}, [24](#ijc31370-bib-0024){ref-type="ref"} A number of these studies initially found an inverse association between MPD and serum E2, but in all [18](#ijc31370-bib-0018){ref-type="ref"}, [20](#ijc31370-bib-0020){ref-type="ref"}, [23](#ijc31370-bib-0023){ref-type="ref"} but one of these[44](#ijc31370-bib-0044){ref-type="ref"} the association disappeared after adjustment for BMI. The influence of MHT use on MPD has also been shown to be largely restricted to women taking combined estrogen plus progestin therapy, rather than estrogen alone.[14](#ijc31370-bib-0014){ref-type="ref"}, [15](#ijc31370-bib-0015){ref-type="ref"}, [16](#ijc31370-bib-0016){ref-type="ref"}, [17](#ijc31370-bib-0017){ref-type="ref"} This provides further support for the results of our study and others, which have not found a strong relationship between MPD and circulating estrogen concentrations in postmenopausal women.

Finally, we found a positive association between MRI‐density and SHBG. Though most studies have also found positive associations between MPD and SHBG,[18](#ijc31370-bib-0018){ref-type="ref"}, [19](#ijc31370-bib-0019){ref-type="ref"}, [21](#ijc31370-bib-0021){ref-type="ref"}, [23](#ijc31370-bib-0023){ref-type="ref"} the biological basis of this finding is unclear. It has been suggested by others that it may be due to residual confounding by adiposity.[19](#ijc31370-bib-0019){ref-type="ref"}, [20](#ijc31370-bib-0020){ref-type="ref"}

Our study has a number of strengths. First, we were able obtain blood samples immediately prior to MRI, to ensure that serum hormone concentrations reflected the hormonal environment at the time of MRI. Furthermore, information on BMI, use of hormonal medications and other breast cancer risk factors were also collected at the time of MRI allowing these variables to be taken into account in terms of participant eligibility and/or analysis. A further strength of the study was that we were able to exclude women who had a cancer diagnosis within the six months following MRI to ensure that we were working with a cancer‐free study population. This limits the potential effect of the presence of a tumor on MRI measurements and serum hormone concentrations. We also examined the relationship between serum androgens (androstenedione, total and bioavailable testosterone) but no difference in serum concentration was observed across any category of BPE or MRI‐density. For simplicity these results have not been presented.

BPE is a promising new marker of breast cancer risk that appears to be independent of breast density, one of the strongest known risk factors for breast cancer. This is the first study to examine the relationship between serum hormone concentrations and BPE and MRI‐density, and as such requires replication. The hormonally responsive nature of BPE, supported by this, and prior studies, suggests that BPE could be a novel imaging marker of risk used to further stratify high‐risk women undergoing breast cancer screening with MRI.

Along with enhanced screening with MRI and mammogram, high‐risk women are also targeted for preventive measures including prophylactic surgeries (e.g., mastectomy, oophorectomy) and chemoprevention (e.g., tamoxifen), both of which can significantly impact quality of life. Efforts are underway to improve breast cancer risk stratification to inform population‐based programs of breast cancer screening and preventive intervention. It is thought that BPE could be used to further optimize risk stratification, supporting efforts to further individualize recommendations for breast cancer screening and prevention, such that women at the highest risk of disease can be targeted for more aggressive interventions and those at lower risk, who will benefit less from the intervention, will not have to undergo an unnecessary procedure or experience the associated side‐effects.

As a new imaging marker of risk we are still working to understand the role BPE might play in breast cancer risk and the relationship to hormonal exposures. If our results are confirmed, future studies should address the impact of including BPE in risk prediction algorithms but should also address the potential of BPE in assessing the impact of other hormonal exposures on the breast. This could include using BPE as an imaging marker of hormonal treatment response in women with breast cancer, and perhaps for use in the identification of novel chemotherapeutic agents.

We would like to extend special thanks to the study participants for volunteering for our study.
